Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A PHASE I STUDY OF ERY974 IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC HEPATOCELLULAR CARCINOMA

NCT05022927 is registered in ClinicalTrials.gov with Chugai Pharmaceutical as lead sponsor.

NCT NCT05022927
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05022927 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A PHASE I STUDY OF ERY974 IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC HEPATOCELLULAR CARCINOMA
Lead sponsor
Chugai Pharmaceutical
Phase
Phase 1
Overall status
Active, not recruiting
Start date
June 1, 2021
Completion date
December 31, 2025
Enrollment
179 (estimated)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma (hcc)